Contact: Frank H. Kerrigon, Director Corporate Communications 
Telephone: (516)-333-8230, ext. 325 

                     E-Z-EM Decontamination Lotion Being Evaluated by 
                  U.S. Military's Foreign Comparative Test (FCT) Program

RSDL BRAND CHEMICAL WARFARE DECONTAMINANT ALREADY BEING USED BY OTHER NATO MEMBER ARMED FORCES

Westbury, New York; October 30, 2001 E-Z-EM, Inc., (AMEX - EZM.A and EZM.B) today announced 
that its Reactive Skin Decontamination Lotion (RSDL), a personal decontamination lotion for 
neutralizing and destroying chemical warfare (CW) agents, is being evaluated in the United 
States Military’s Foreign Comparative Test (FCT) program. The full testing program will 
include evaluating RSDL as a decontaminant for biological agents, such as anthrax, as well 
as for CW agents.

About RSDL RSDL was invented by Defense Research Establishments of the Canadian Department 
of National Defense at Ottawa, Ontario and Suffield, Alberta. The Department of National 
Defense has licensed RSDL to O’Dell Engineering Ltd., who has subcontracted E-Z-EM Canada Inc. 
to be the exclusive global manufacturer of the product. RSDL is currently in use with all 
the service branches of the Canadian Armed Forces, and with the Dutch Armed Forces, the 
Australian Army and the Irish Armed Forces, among others. In addition, several specialist 
organizations such as the Organization for the Prohibition of Chemical Weapons (OPCW), 
whose personnel are required to handle CW weapons as part of their work, also use RSDL for 
their own protection during sensitive missions.

The FCT Program

The FCT program is the U.S. Military’s method of evaluating foreign-designed products such as 
RSDL that may offer the potential to enhance the Military’s capabilities or provide significant 
advantages in cost or function over currently utilized products. The RSDL submission was 
proposed and written by the U.S. Marine Corps with the support of the U.S. Air Force and 
the U.S. Army Medical Staff at Fort Detrick, Maryland. Once included in the review process, 
RSDL became the top-rated Navy FCT new product for the Military’s fiscal year 2000-2001. The 
FCT evaluation is verifying the efficacy of RSDL against chemical and biological warfare 
agents, and is testing for user suitability and safety. If the product is found to be 
acceptable, the program also provides for complete documentation and cost assumption by the 
Military related to 510(k) filing with the FDA.

If RSDL successfully passes through the FCT program, it can then be recommended as an 
acceptable product for all four service branches of the Armed Forces to replace or augment 
their existing decontamination products. The FCT project office would then be able to advocate 
purchases of RSDL under an IDIQ (Indefinite Delivery/ Indefinite Quantity) contract negotiated 
as part of the FCT program. Any purchase decisions may then be made at the individual service 
branch level as determined by need and budget.

Recently completed initial efficacy tests have shown RSDL to meet the Canadian Government and 
manufacturer’s claims, and the full scale FCT evaluation and submission program has been given 
the go-ahead.

Commenting on the announcement, Anthony A. Lombardo, President and Chief Executive Officer of 
E-Z-EM said, "We are extremely pleased that RSDL is included in the FCT program as a possible 
replacement or enhancement for existing powder decontamination systems, which can only be used 
in limited intact skin applications. RSDL has the potential for use in decontaminating all skin 
surfaces, including the eyes, nose, mouth and hair, and is being tested for safety in wounds. 
Unlike other decontamination systems, liquid RSDL reacts very rapidly - within a matter of 
seconds - with deadly nerve agents to chemically reduce them to a non-toxic mix. The product 
is able to neutralize a wide variety of CW agents, including Mustard and Lewisite, and is 
being evaluated as a decontaminant for biological agents, such as anthrax, as well.

"Other powder systems can absorb these agents but require much greater time to reduce their 
toxicity," said Lombardo. "And the mix must be removed or the danger from the nerve agent 
remains. This is not practical in military situations. In addition, RSDL has been observed 
to improve the seal of breathing devices such as gas masks, where powder absorbent systems 
tend to have the opposite effect."

E-Z-EM Canada Inc., a Montreal subsidiary of E-Z-EM, and O’Dell Engineering Ltd. of Cambridge, 
Ontario, have a long-term agreement to commercialize the product. As part of their exclusive 
partnership agreement, E-Z-EM Canada assumes the manufacturing of RSDL worldwide, while O’Dell, 
the license holder under the Canadian government, is responsible for all sales and marketing 
aspects. 

About E-Z-EM, Inc. 

E-Z-EM is the world’s largest manufacturer of contrast agents for gastrointestinal radiology. 
E-Z-EM Canada, a wholly-owned subsidiary, is a primary manufacturing site for liquid contrast 
agents, custom contract pharmaceuticals and cosmetic products. Another subsidiary, 
AngioDynamics, Inc., manufactures a wide range of products, including angiographic, 
vascular access, thrombolytic, angioplasty, stents, as well as drainage products. The Company’s 
Enteric Products, Inc., subsidiary, develops, manufactures and markets tests for detection of 
the ulcer- and cancer-causing bacterium Helicobacter pylori. For additional information, 
please contact Frank Kerrigon at 516-333-8230, ext. 325, (E-mail: fkerrigon@ezem.com) or 
visit our corporate web site at www.ezem.com.

The statements made in this document contain certain forward looking statements that involve 
a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", 
"plans", "believes", "seeks", "estimates", or variations of such words and similar expressions, 
are intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, general market 
conditions, competition and pricing, as well as the risk factors listed from time to time in 
the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter 
ended March 3, 2001,as well as its Annual Report on Form 10-K for the year ended June 3, 2000, 
may affect the actual results achieved by the Company.

End